| Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008 MA Pfaller, DR Andes, DJ Diekema, DL Horn, AC Reboli, C Rotstein, ... PloS one 9 (7), e101510, 2014 | 471 | 2014 |
| Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada A Wagg, B Franks, B Ramos, T Berner Canadian Urological Association Journal 9 (9-10), 343, 2015 | 117 | 2015 |
| Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance® registry DL Horn, AG Freifeld, MG Schuster, NE Azie, B Franks, CA Kauffman Mycoses 57 (11), 652-658, 2014 | 81 | 2014 |
| Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance® registry analysis S Husain, FP Silveira, N Azie, B Franks, D Horn Medical mycology 55 (3), 269-277, 2017 | 74 | 2017 |
| Prospective antifungal therapy (PATH) alliance®: focus on mucormycosis DP Kontoyiannis, N Azie, B Franks, DL Horn Mycoses 57 (4), 240-246, 2014 | 72 | 2014 |
| Validation of cancer cases using primary care, cancer registry, and hospitalization data in the United Kingdom AV Margulis, J Fortuny, JA Kaye, B Calingaert, M Reynolds, E Plana, ... Epidemiology 29 (2), 308-313, 2018 | 65 | 2018 |
| Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo Acknowledged European Urology 77 (1), 119-128, 2020 | 60 | 2020 |
| Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus FG Hage, J Heo, B Franks, L Belardinelli, B Blackburn, W Wang, ... American Heart Journal 157 (4), 771-776, 2009 | 60 | 2009 |
| Drug-drug interaction associated with mold-active triazoles among hospitalized patients D Andes, N Azie, H Yang, R Harrington, C Kelley, RD Tan, EQ Wu, ... Antimicrobial agents and chemotherapy 60 (6), 3398-3406, 2016 | 56 | 2016 |
| Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial L Rostaing, B Charpentier, M Glyda, P Rigotti, F Hettich, B Franks, ... American Journal of Transplantation 13 (7), 1724-1733, 2013 | 46 | 2013 |
| The performance of wearable sensors in the detection of SARS-CoV-2 infection: a systematic review M Mitratza, BM Goodale, A Shagadatova, V Kovacevic, J Van de Wijgert, ... The Lancet Digital Health 4 (5), e370-e383, 2022 | 44 | 2022 |
| Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance® registry D Neofytos, S Huprikar, A Reboli, M Schuster, N Azie, B Franks, D Horn European journal of clinical microbiology & infectious diseases 33, 135-141, 2014 | 42 | 2014 |
| Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial F Saad, J de Bono, N Shore, K Fizazi, Y Loriot, M Hirmand, B Franks, ... European urology 67 (2), 223-230, 2015 | 39 | 2015 |
| Persistence with mirabegron versus tolterodine in patients with overactive bladder VW Nitti, ES Rovner, B Franks, G Muma, T Berner, A Fan Am J Pharm Benefits 8 (2), e25-e33, 2016 | 35 | 2016 |
| Introducing PIONEER: a project to harness big data in prostate cancer research MI Omar, MJ Roobol, MJ Ribal, T Abbott, PM Agapow, S Araujo, ... Nature Reviews Urology 17 (6), 351-362, 2020 | 34* | 2020 |
| Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis A Perlmutter, J Cather, B Franks, E Jaracz, A Menter Journal of the American Academy of Dermatology 58 (1), 116-124, 2008 | 31 | 2008 |
| Effect of potentially inappropriate use of antimuscarinic medications on healthcare use and cost in individuals with overactive bladder BT Suehs, C Davis, B Franks, TE Yuran, D Ng, J Bradt, J Knispel, ... Journal of the American Geriatrics Society 64 (4), 779-787, 2016 | 27 | 2016 |
| Variation in cardiovascular risk related to individual antimuscarinic drugs used to treat overactive bladder: a UK cohort study A Arana, AV Margulis, LJ McQuay, R Ziemiecki, JL Bartsch, KJ Rothman, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38 (6 …, 2018 | 24 | 2018 |
| Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome WB White, E Siddiqui, T Tat, B Franks, CR Schermer Journal of the American Society of Hypertension 12 (11), 768-778. e1, 2018 | 23 | 2018 |
| Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom A Arana, AV Margulis, C Varas‐Lorenzo, CL Bui, A Gilsenan, LJ McQuay, ... Pharmacoepidemiology and Drug Safety 30 (2), 237-247, 2021 | 22 | 2021 |
Andrea V MargulisResearch Triangle Institute - Health SolutionsVerified email at post.harvard.edu
